210 related articles for article (PubMed ID: 14718785)
21. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
22. Resistance to trastuzumab: a necessary evil or a temporary challenge?
Cardoso F; Piccart MJ; Durbecq V; Di Leo A
Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
24. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody therapy for breast cancer: herceptin.
Finn RS; Slamon DJ
Cancer Chemother Biol Response Modif; 2003; 21():223-33. PubMed ID: 15338747
[No Abstract] [Full Text] [Related]
26. Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Spector N
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S94-9. PubMed ID: 18777948
[TBL] [Abstract][Full Text] [Related]
27. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
28. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
[TBL] [Abstract][Full Text] [Related]
30. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
31. HER2/neu in the management of invasive breast cancer.
Meric F; Hung MC; Hortobagyi GN; Hunt KK
J Am Coll Surg; 2002 Apr; 194(4):488-501. PubMed ID: 11949754
[No Abstract] [Full Text] [Related]
32. HER-2 signaling and inhibition in breast cancer.
Browne BC; O'Brien N; Duffy MJ; Crown J; O'Donovan N
Curr Cancer Drug Targets; 2009 May; 9(3):419-38. PubMed ID: 19442060
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab and breast cancer: developments and current status.
Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
[TBL] [Abstract][Full Text] [Related]
34. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
Kurosumi M
Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
[No Abstract] [Full Text] [Related]
35. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
37. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
Widakowich C; Dinh P; de Azambuja E; Awada A; Piccart-Gebhart M
Anticancer Agents Med Chem; 2008 Jun; 8(5):488-96. PubMed ID: 18537532
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab--mechanism of action and use in clinical practice.
Hudis CA
N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
[No Abstract] [Full Text] [Related]
39. The development and clinical use of trastuzumab (Herceptin).
Harries M; Smith I
Endocr Relat Cancer; 2002 Jun; 9(2):75-85. PubMed ID: 12121832
[TBL] [Abstract][Full Text] [Related]
40. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
Bonneterre ME; Bonneterre J
Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
